文献速递主动脉疾病

脯氨酰羟化酶抑制剂JNJ促进糖尿病小鼠腹主动脉瘤进展

Treatment with the Prolyl Hydroxylase Inhibitor JNJ Promotes Abdominal Aortic Aneurysm Progression in Diabetic Mice.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2021-12-03

在糖尿病与非糖尿病雄性C57BL/6J小鼠中经主动脉内弹性蛋白酶灌注诱导腹主动脉瘤,每日给予PHD抑制剂JNJ-42041935(150 mmol/kg)或溶媒共14天。JNJ预处理可增强糖尿病小鼠主动脉HIF-1α靶基因表达并促进动脉瘤进展;糖尿病与非糖尿病患者的主动脉瘤切片中HIF-1α与VEGF-A免疫染色未见糖尿病状态相关差异。

要点

  • 糖尿病小鼠实验性主动脉中HIF-1α靶基因表达降低45%–95%。
  • JNJ预处理可增强糖尿病小鼠主动脉HIF-1α靶基因表达并促进动脉瘤进展。
  • 人主动脉瘤组织HIF-1α与VEGF-A免疫染色未见糖尿病状态相关差异。

核心结论

  • 小分子PHD抑制剂治疗可减轻或抵消高血糖小鼠实验性腹主动脉瘤进展的受损,提示PHD活性失调可能参与糖尿病介导的动脉瘤抑制。

研究设计与样本

  • 在糖尿病与非糖尿病雄性C57BL/6J小鼠中经主动脉内弹性蛋白酶灌注诱导腹主动脉瘤。
  • 自腹主动脉瘤诱导前一日开始每日给予PHD抑制剂JNJ-42041935(150 mmol/kg)或单用溶媒,共14天。
  • 通过超声与组织病理学评估对腹主动脉瘤进展的影响。
  • 通过定量逆转录聚合酶链反应检测主动脉HIF-1α、其三个靶基因及巨噬细胞来源介质的表达。
  • 对伴与不伴糖尿病的腹主动脉瘤患者动脉瘤切片(每组2例)进行HIF-1α与VEGF-A免疫染色。

主要发现

  • 实验性糖尿病主动脉中HIF-1α靶基因(促红细胞生成素、VEGF-A与葡萄糖转运蛋白-1)表达降低45%–95%。
  • 糖尿病小鼠中直径扩大同样受限,组织病理学上管壁弹性蛋白降解、白细胞浸润与新生血管形成(毛细血管密度与长度降低)亦受限。
  • 腹主动脉瘤诱导前给予JNJ预处理可增强糖尿病小鼠主动脉HIF-1α靶基因表达及动脉瘤进展,并伴随巨噬细胞VEGF-A与基质金属蛋白酶2 mRNA表达增高。
  • 人主动脉组织免疫组化染色中HIF-1α或VEGF-A表达未见糖尿病状态相关差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Prolyl hydroxylase domain containing proteins (PHD) rigorously regulate intracellular hypoxia inducible factor-1 (HIF-1) protein expression and activity. Diabetes impairs PHD activity and attenuates abdominal aortic aneurysm (AAA) progression. The extent to which dysregulated PHD activity contributes to diabetes mediated AAA suppression remains undetermined. METHODS: AAAs were induced in diabetic and non-diabetic male C57BL/6J mice via intra-aortic elastase infusion. A PHD inhibitor (JNJ-42041935, aka "JNJ", 150 mmol/kg) or vehicle alone was administered daily starting one day prior to AAA induction for 14 days. Influences on AAA progression was assessed via ultrasonography and histopathology. Expression of aortic HIF-1α, three of its target genes and macrophage derived mediators were assayed via quantitative reverse transcription polymerase chain reaction. Aneurysmal sections from AAA patients with and without diabetes (two patients in each group) were immunostained for HIF-1α and vascular endothelial growth factor (VEGF)-A. RESULTS: Expression of HIF-1α target genes (erythropoietin, VEGF-A, and glucose transporter-1) was reduced by 45% - 95% in experimental diabetic aortas. Diameter enlargement was similarly limited, as were mural elastin degradation, leukocyte infiltration, and neo-angiogenesis (reduced capillary density and length) on histopathology. Pre-treatment with JNJ prior to AAA initiation augmented aortic HIF-1α target gene expression and aneurysm progression in diabetic mice, along with macrophage VEGF-A and matrix metalloproteinase 2 mRNA expression. No differences were noted in HIF-1α or VEGF-A expression on aortic immunohistochemical staining of human aortic tissue as a function of diabetes status. CONCLUSION: Small molecule PHD inhibitor treatment reduces or offsets impairment of experimental AAA progression in hyperglycemic mice, highlighting the potential contribution of dysregulated PHD activity to diabetes mediated aneurysm suppression.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Guo J, Shoji T, Ge Y, et al. Treatment with the Prolyl Hydroxylase Inhibitor JNJ Promotes Abdominal Aortic Aneurysm Progression in Diabetic Mice. Eur J Vasc Endovasc Surg. 2021. PMID: 34872812. doi:10.1016/j.ejvs.2021.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。